You just read:

ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema

News provided by

ThromboGenics

05 Sep, 2013, 06:30 BST